Stand Up To Cancer has awarded 10 SU2C Catalyst clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials across a variety of cancers, in a program supported by industry.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
